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Abstract. Flea-borne (murine) typhus is a global rickettsiosis caused by Rickettsia typhi. Although flea-borne
typhus is no longer nationally notifiable, cases are reported for surveillance purposes in a few U.S. states. The infec-
tion is typically self-limiting, but may be severe or life-threatening in some patients. We performed a retrospective
review of confirmed or probable cases of fatal flea-borne typhus reported to the Texas Department of State Health
Services during 1985–2015. When available, medical charts were also examined. Eleven cases of fatal flea-borne
typhus were identified. The median patient age was 62 years (range, 36–84 years) and 8 (73%) were male. Patients
presented most commonly with fever (100%), nausea and vomiting (55%), and rash (55%). Respiratory (55%) and
neurologic (45%) manifestations were also identified frequently. Laboratory abnormalities included thrombocytopenia
(82%) and elevated hepatic transaminases (63%). Flea or animal contact before illness onset was frequently reported
(55%). The median time from hospitalization to administration of a tetracycline-class drug was 4 days (range, 0–5 days).
The median time from symptom onset to death was 14 days (range, 1–34 days). Flea-borne typhus can be a life-
threatening disease if not treated in a timely manner with appropriate tetracycline-class antibiotics. Flea-borne
typhus should be considered in febrile patients with animal or flea exposure and respiratory or neurologic symptoms
of unknown etiology.
INTRODUCTION
Flea-borne typhus, also known as endemic or murine
typhus, is a rickettsial zoonosis caused by Rickettsia typhi
that occurs predominantly in warm, coastal areas of the
world, including certain parts of the United States.1 Dur-
ing the early 1940s, approximately 2,000–5,000 cases were
reported annually, but sanitation and vector control cam-
paigns significantly reduced the number of flea-borne typhus
cases in the United States. In 1995, flea-borne typhus was
removed from the list of nationally notifiable diseases,2 mak-
ing the contemporary prevalence of flea-borne typhus in the
United States difficult to ascertain3,4; nonetheless, flea-borne
typhus remains a reportable disease in 14 U.S. states (CA,
HI, IL, IN, MI, MN, MS, NE, NH, OH, OR, PA, TX, and WA).
The majority of U.S. cases occur in Texas, which reported
3,048 confirmed or probable cases of flea-borne typhus
during 1985–2015 (Texas Department of State Health
Services, unpublished data). Flea-borne typhus is often
described as a relatively mild and self-limiting rickettsiosis;
nonetheless, a spectrum of severe manifestations is also
recognized,5–10 and the disease may be fatal in as many as
5% of patients for whom appropriate antibiotic therapy is
delayed or not provided.11 The objective of this study was
to describe the clinical and epidemiologic features associ-
ated with fatal flea-borne typhus cases in Texas.
METHODS
Flea-borne typhus cases are reported in Texas by using
a standardized case report form that includes demographic
information, various clinical characteristics, duration of ill-
ness, animal and arthropod exposure, travel history, and
outdoor activities prior to illness onset. The data were
reviewed for confirmed and probable fatal cases identified
during 1985–2015. When available, medical charts were
examined for supplemental information relating to comor-
bidities, clinical presentation, antibiotic therapy, laboratory
results, and diagnosis at time of death. Diagnostic test results
were generated by multiple commercial laboratories or by
state or national reference centers. All personally identifiable
information was removed from the case investigation forms
and medical charts before review at the Centers for Disease
Control and Prevention (CDC). This case series protocol was
reviewed and determined to qualify as non-research and was
exempt from further review according to the CDC’s National
Center for Emerging and Zoonotic Infectious Diseases insti-
tutional procedures.
A confirmed case was defined as a patient with a clini-
cally compatible illness and 1) a 4-fold or greater rise in
antibody titer to R. typhi antigens by using an indirect
immunofluorescence antibody (IFA) assay in acute and con-
valescent phase serum specimens; or 2) a single reciprocal
IFA titer ≥ 1,024; or 3) a positive polymerase chain reaction
(PCR) assay to R. typhi; or 4) demonstration of typhus
group Rickettsia sp. antigens by an immunohistochemical
stain in tissue; or 5) isolation of R. typhi from clinical speci-
men. A probable case was defined as a patient with a clini-
cally compatible illness and a reciprocal IgG or IgM IFA titer
of ≥ 64.
RESULTS
Eleven confirmed or probable fatal cases of flea-borne
typhus were reported in Texas during 1985–2015 (Figure 1).
The median age of the patients was 62 years (range, 36–
84 years) and 9 (82%) were > 50 years of age. Eight (73%)
patients were male and seven (64%) were of Hispanic ethnicity
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(Table 1). Six patients met the criteria for a confirmed case;
four (67%) patients were diagnosed with single reciprocal
IFA titers ≥ 1,024 (range, 1,024–4,096); one patient demon-
strated a 4-fold rise in antibody titer; one patient had a skin
biopsy specimen that stained positive for antigens of a
typhus group Rickettsia sp. (Figure 2) and a reciprocal IFA
titer of ≥ 4,096 (Table 1). Five patients met the criteria for a
probable case and were classified using a reciprocal sero-
logic titer < 1,024 (range, 64–512). Of these, one had recipro-
cal IgG and IgM titers of 256 and 2,048, respectively, 5 days
post-illness onset, and one had reciprocal IgG and IgM titers
of 64 and 512, respectively, 9 days after illness onset
(Table 1). No patients were diagnosed by PCR or culture iso-
lation. Five (38%) patients were additionally tested by an IFA
assay using antigens of Rickettsia rickettsii (the agent of
Rocky Mountain spotted fever [RMSF]); 2(40%), 1(20%),
and 2(40%) had reciprocal IgG antibody titers to this anti-
gen at < 64, 128, and 512, respectively. Both patients with
R. rickettsii titer of 512 had R. typhi titers ≥ 4,096. For the
patients with reciprocal titers to both rickettsial antigens,
the titer to R. typhi was consistently 4-fold or greater than
the titer to R. rickettsii. Two additional patients were identi-
fied in 1999 and 2001. These patients each had reciprocal
IgG antibody titers to R. typhi of 512; however, no addi-
tional case information was available on their clinical course
of illness and they were excluded from further analysis.
Eight of 11 (73%) case report forms contained informa-
tion on flea or animal contact in the 2 weeks before illness
onset. Three (27%) patients reported fleas in the home,
three (27%) patients had at least one dog, and four (36%)
patients either owned a cat or cared for stray cats. Two
(18%) patients reported an opossum living within or next
to their home (Table 1). One (9%) patient reported hunting
in south Texas before illness onset, but no specific animal
species were named. Cases occurred year-round with no
apparent seasonality (Table 1).
All patients were hospitalized. At hospital presentation,
fever was reported for 11 (100%) patients. The median tem-
perature was 101.9°F (range, 99–104.6°F). Thrombocytope-
nia (82%) and elevated hepatic transaminase levels (64%)
were the most frequently reported laboratory abnormalities.
Six (55%) patients reported one or more respiratory-related
symptom (i.e., cough), or diagnosis (i.e., pneumonia, pulmo-
nary edema, or acute respiratory distress syndrome). Rash
was reported in 55% of patients, and was described as
macular and maculopapular (50%) or petechial (50%), and
was distributed across the palms and soles (33%), arms
and legs (33%), and trunk (67%) (Table 2). Rash was fre-
quently reported as a late finding, occurring > 7 days after
initial illness onset.
The median time from symptom onset to hospitalization
was 8 days (range, 1–21 days), and the median time from
symptom onset to death was 14 days (range, 1–34 days).
Four (36%) patients sought medical care during their first
week of illness; two cases were diagnosed with urinary tract
infections unrelated to R. typhi infection and prescribed
non-tetracycline class antibiotics, one patient received an
unknown antibiotic for an unspecified illness, and the fourth
patient had no information available. Two (18%) patients
received a sulfa-containing antibiotic during their illness.
Seven (64%) patients received a tetracycline-class antibi-
otic (doxycycline or tetracycline) during hospitalization. The
median number of days from hospital admission to initiation
of a tetracycline-class antibiotic was 4 (range, 0–5 days).
The median time from symptom onset to initiation of a
tetracycline-class drug was 9 days (range, 4–17 days).
Additional data abstracted from medical charts were
available for eight patients. Of these, neurologic complica-
tions were present at hospital admission in five (63%)
patients and included meningitis, encephalitis, vertigo, diz-
ziness, seizure, and coma. Two of the five patients were
obtunded on presentation and never regained conscious-
ness. At hospital presentation, two (25%) patients had
acute kidney injury. Comorbidities were for five (63%) of
these patients including three (37%) with a history of alco-
hol abuse, one (13%) with chronic renal disease, congestive
heart failure, and Type 2 diabetes mellitus, and one (13%)
with a preexisting seizure disorder.
DISCUSSION
To our knowledge, this is the largest series of patients
with fatal flea-borne typhus. The case fatality rate (CFR)
in Texas during this period (0.4%) was not significantly
different from the CFR described for 200 cases of flea-
borne typhus from Texas that occurred during 1980–198412
(1%, P = 0.30). During the pre-antibiotic era, CFRs of flea-
borne typhus varied regionally, but the overall CFR for
TABLE 1
Epidemiological and laboratory data of patients with confirmed or probable fatal flea-borne typhus in Texas, 1985–2015
Patient (age/sex) Ethnicity Animal exposure Flea exposure Onset (month/year) Days from onset to death Case status Reciprocal IgG IFA titer(s) to Rickettsia typhi
81/F Hispanic Yes*† Unknown June 1985 11 Confirmed 64, 1,024
67/M Non-Hispanic No No September 1986 17 Probable 256
36/M Hispanic Unknown Unknown June 1991 8 Confirmed ≥1,024
72/M Hispanic Unknown Unknown June 1995 34 Confirmed ≥1,024
73/F Hispanic Yes† Yes December 1998 6 Probable 512§
53/M Hispanic Unknown Unknown January 2007 6 Confirmed ≥1,024
36/M Non-Hispanic Yes*‡ Yes April 2012 13 Confirmed ≥4,096
50/M Non-Hispanic Yes† Unknown May 2013 20 Confirmed ≥4,096¶
55/M Hispanic Yes†‡ Yes May 2013 14 Probable 256
84/F Hispanic Unknown Unknown November 2014 12 Probable 64∥
62/M Unknown Yes‡ Unknown January 2015 9 Probable 256**
IFA = indirect immunofluorescence antibody.
†Reported exposure to: * opossum, †cat, ‡ dog.
§Patient also had 1:40 titer to R. typhi by slide agglutination assay.
¶Patient also had a skin biopsy specimen positive for a typhus group Rickettsia sp.by immunohistochemical stain.
∥Patient also had a reciprocal IgM IFA titer of 512 on same date.
**Patient also had a reciprocal IgM IFA titer of 2,048 on same date.
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18,337 U.S. cases during 1940–1944 was 4.6%.11–14 Among
the cases reviewed herein, a high proportion were male
(73%) and over the age of 50 years (82%). More than 70%
of the patients in this series who were treated with a
tetracycline-class antibiotic did not receive this drug until
the second week of illness, emphasizing the need for
prompt administration of appropriate antimicrobial therapy
to reduce fatal outcome.
Respiratory signs or symptoms were noted for more than
half of the patients in this series. The frequency of respira-
tory manifestations have been recognized for many years;
indeed, an early summary of flea-borne typhus in Texas
noted, “few diseases present so much subjective respira-
tory symptoms with so little objective findings.”15 Previous
literature reported 14–59% of flea-borne typhus patients
had respiratory symptoms.12,16,17 Neurologic manifestations
FIGURE 1. Texas counties with fatal flea-borne typhus by case count, 1985–2015.
FIGURE 2. Histopathological and immunohistochemical appearance of a skin biopsy specimen from a patient with a fatal typhus
group rickettsiosis.
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were also seen in more than half of the patients for whom addi-
tional data were available, and previous literature has described
neurologic manifestations in 15–45% of patients.17,18 Our find-
ings are consistent with previous literature and suggest that
respiratory and neurologic complications from R. typhi infection
may occur frequently in severe cases.6,16,18–21 The frequency of
respiratory and neurologic manifestations identified in this series
may have been confounded by the advanced stage of disease
that patients presented at initial hospital presentation. Previous
literature reports risk of complications increases with age.
Therefore, older patients (> 50 years) may be at greater risk for
poor outcomes.20,22,23
Of the seven patients with elevated hepatic transaminases,
three (43%) had a history of alcohol abuse. Clinicians may
have attributed elevated hepatic transaminases to complica-
tions from alcohol abuse; however, hepatic inflammation has
also been documented with severe flea-borne typhus.24,25
Two patients in this case series were treated with sulfa-
containing antibiotic after illness onset and before hospital
admission. Multiple historical and contemporary case reports
describe adverse outcomes in flea-borne typhus patients
treated with sulfa-containing antibiotics.11,18,26 Similar obser-
vations have been identified in patients with other rickettsial
diseases, particularly RMSF and Ehrlichia chaffeensis ehrlichi-
osis.27 Case–control studies are needed to better assess
the potential contraindication of sulfa drugs in the treatment
of patients with rickettsiosis, including flea-borne typhus.
Glucose-6-phosphate dehydrogenase deficiency was not
identified or assessed as a comorbidity in any of the patients
in this series; nonetheless, this condition has been previ-
ously associated with life-threatening disease in patients
with flea-borne typhus28 as well as other rickettsioses
including RMSF29 and Mediterranean spotted fever (caused
by Rickettsia conorii)30 and scrub typhus (caused by
Orientia tsutsugamushi).28
Five cases of fatal flea-borne typhus have been reported
previously in detail.20,26,31 These patients, from the United
States and Spain, presented with similar demographic and
clinical characteristics to the patients in our case series.
Their median age was 56 years (range, 46–81 years), three
(60%) were male, one (20%) reported contact with rodents,
four (80%) reported fever, one (20%) had rash, two (40%)
had thrombocytopenia, one (20%) developed respiratory
manifestations, and one (20%) developed neurologic mani-
festations. The median time from illness onset to death
was 13 days (range, 11–15 days). Importantly, two (40%)
received a sulfa-containing antibiotic.
In previous outbreaks, as many as 70% of patients of
flea-borne typhus have required hospitalization and as
many as 30% of these patients require admission to an
intensive care unit32; nonetheless, even in areas such as
Texas where the disease is endemic, a correct diagnosis of
flea-borne typhus is often delayed for 10 or more days.33
The signs and symptoms of even advanced disease may
be nonspecific and can hamper a timely diagnosis. Delay in
treatment with a tetracycline-class antibiotic is associated
with poorer outcomes including death. Doxycycline is the
drug of choice for treating rickettsiosis in patients of all
ages.34 Flea-borne typhus should be considered in patients
with a history of animal or flea exposure and a nonspecific
febrile illness of > 3 days.22,31,34 Absence of rash should



































































































































































































































































































































































































































particularly as it often occurs late in the development of
disease, as identified in this series. A history of recent
exposure to fleas or animals can provide valuable clues
into potential etiology of unknown illness; however, absence
of known animal or flea exposures does not rule out flea-
borne typhus in an endemic area, as patients may be
unaware of these exposures.
This case series had several limitations inherent to stud-
ies that use data acquired predominantly or exclusively
through passive surveillance, including incompleteness of
information reported to the state health department, and
inability to review medical charts for some of the patients.
In contrast to many other rickettsioses endemic in the
United States, typhus group rickettsioses are not nationally
notifiable. In that context, there are no nationally recognized
laboratory criteria to define confirmed or probable cases of
typhus group rickettsioses. Because each of the fatal cases
were from Texas, we applied the case definitions developed
by the Texas Department of State Health Services. None-
theless, a single antibody titer is not a universally accepted
laboratory criterion for a confirmed case. Furthermore,
because this was a retrospective study, the serological
data were generated by multiple laboratories during a
30-year period and therefore lack consistency with respect
to reagents, methods, and interpretation by laboratory per-
sonnel. Finally, this study lacked a control group to com-
paratively assess risk factors. Future case–control studies
could help identify risk factors for severe and fatal out-
comes in patients with flea-borne typhus.
Infection with Rickettsia felis, a typhus-like Rickettsia,
has been documented in at least one patient in Texas.35
Because R. typhi and R. felis occur sympatrically in fleas
in Texas, it is possible that R. felis may be responsible for
some cases of flea-borne typhus36–38; however, vertebrates
infected with R. felis characteristically produce antibodies
that cross-react with antigens of spotted fever group rick-
ettsiae rather than typhus group rickettsiae.39,40 Antibodies
reactive with spotted fever group rickettsiae were detected
in five of the patients in this series for whom these tests
were performed, but each of these patients had corre-
sponding typhus group titers that were at least 4-fold
higher. Additionally, R. typhi typically causes more severe
disease in humans than R. felis,6,19,22 and to our knowledge
there are no reported fatal cases of human infection with
R. felis. A previous study of Texas patients for whom a flea-
borne rickettsiosis was suspected found evidence of infec-
tion with R. typhi in 22% versus infection with R. felis in
only 2%, by using species-specific recombinant antigens,
to suggest that infections with R. typhi are more prevalent
in humans in Texas than are infections with R. felis.41 In this
context, we believe each of the fatal cases described herein
represented infection with R. typhi rather than R. felis.
A confirmed human infection with Rickettsia prowazekii,
another typhus group Rickettsia species, was described
in 2001 that may have been acquired in south Texas42 and
serological evidence of infection with R. prowazekii was
confirmed by cross-adsorption assays in two of 19 home-
less persons in Houston, TX, with antibodies reactive to
typhus group rickettsiae.43 Rickettsia prowazekii has been
detected in an Amblyomma tick collected in northern
Mexico,44 and this species is also found in south Texas.45
In this context, it is also possible that some of the cases in
this case series were caused by R. prowazekii rather than
R. typhi.
Clinicians may want to consider older age, delay in treat-
ment, and a history of alcohol abuse as potential risk fac-
tors for severe flea-borne typhus; however, case–control
studies need to be conducted to identify risk factors for
severe disease. Severity of disease may be mitigated by early
diagnosis and initiation of appropriate tetracycline-class anti-
biotic therapy. Clinicians should be aware that flea-borne
typhus is a potentially serious illness and should be consid-
ered in febrile patients with animal or flea exposure and
respiratory or neurologic signs of unknown etiology.
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